CD47 and glioblastoma: To examine how IgG subclass may affect antibody-mediated cellular phagocytosis (ADCP) effects and CD47-Sirp disruption-induced phagocytosis, we treated glioblastoma cells with an IgG1-antibody against an unrelated target, epidermal growth factor receptor (EGFR, cetuximab).